Sofinox

Sodium fusidate, an antibiotic derived from Fusidium coccineum, exerts powerful antibacterial activity against a number of gram-positive organisms. Staphylococci, including the strains resistant to penicillin or other antibiotics, are particularly susceptible to sodium fusidate.
The therapeutic efficacy of topically applied sodium fusidate is due partly to pronounced antibacterial activity of sodium fusidate against the organisms responsible for skin infection, and partly to the unique ability of this antibiotic to penetrate intact skin.
Fusidate is widely distributed into tissues and body fluids. It has been found in the fetal circulation and in breast milk. About 95% or more of fusidate in the circulation is bound to plasma proteins. Fusidate has a plasma half-life of about 10 to 15 hours. It is excreted in the bile, almost entirely as metabolites, some of which have weak antimicrobial activity. About 2% appears unchanged in the faeces. Little is excreted in the urine or removed by haemodialysis.